BR112022009611A2 - Anticorpos anti-ror-2 e métodos de uso - Google Patents
Anticorpos anti-ror-2 e métodos de usoInfo
- Publication number
- BR112022009611A2 BR112022009611A2 BR112022009611A BR112022009611A BR112022009611A2 BR 112022009611 A2 BR112022009611 A2 BR 112022009611A2 BR 112022009611 A BR112022009611 A BR 112022009611A BR 112022009611 A BR112022009611 A BR 112022009611A BR 112022009611 A2 BR112022009611 A2 BR 112022009611A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- ror
- ror2
- methods
- inter alia
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000016978 Orphan receptors Human genes 0.000 abstract 1
- 108070000031 Orphan receptors Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Abstract
ANTICORPOS ANTI-ROR-2 E MÉTODOS DE USO. São fornecidos neste documento, inter alia, anticorpos (por exemplo, anticorpos humanizados, anticorpos monoclonais), fragmentos de anticorpos (por exemplo, scFvs) e composições de anticorpos (por exemplo, receptores de antígenos quiméricos, anticorpos biespecíficos), que ligam receptor órfão 2 (ROR2) tipo tirosina quinase humana com alta eficiência e especificidade. Os anticorpos e as composições de anticorpos fornecidos neste documento incluem novas CDRs de domínio de cadeia leve e pesada e regiões framework e são, inter alia, úteis para diagnosticar e tratar câncer e outras doenças relativas a ROR2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962936900P | 2019-11-18 | 2019-11-18 | |
PCT/US2020/061130 WO2021102055A1 (en) | 2019-11-18 | 2020-11-18 | Anti-ror-2 antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022009611A2 true BR112022009611A2 (pt) | 2022-08-09 |
Family
ID=75981012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022009611A BR112022009611A2 (pt) | 2019-11-18 | 2020-11-18 | Anticorpos anti-ror-2 e métodos de uso |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230192846A1 (pt) |
EP (1) | EP4061848A4 (pt) |
JP (1) | JP2023502108A (pt) |
KR (1) | KR20220113951A (pt) |
CN (1) | CN116018353A (pt) |
AU (1) | AU2020388577A1 (pt) |
BR (1) | BR112022009611A2 (pt) |
CA (1) | CA3161617A1 (pt) |
IL (1) | IL293026A (pt) |
MX (1) | MX2022005949A (pt) |
WO (1) | WO2021102055A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202110131SA (en) * | 2019-03-26 | 2021-10-28 | Univ California | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers |
WO2023164618A1 (en) * | 2022-02-25 | 2023-08-31 | Bioatla, Inc. | Cancer treatment with a conditionally active anti-ror2 antibody-drug conjugate |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2662041A1 (en) * | 2006-09-08 | 2008-03-13 | Genentech, Inc. | Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders |
GB201506407D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
CA3011817A1 (en) * | 2016-01-20 | 2017-07-27 | The Scripps Research Institute | Ror2 antibody compositions and related methods |
SI3455261T1 (sl) * | 2016-05-13 | 2023-01-31 | Bioatla, Inc. | Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh |
MX2018015592A (es) * | 2016-06-14 | 2019-04-24 | Xencor Inc | Anticuerpos inhibidores de puntos de control biespecificos. |
CA3099487A1 (en) * | 2017-07-20 | 2019-01-24 | Nbe-Therapeutics Ag | Human antibodies binding to ror2 |
-
2020
- 2020-11-18 JP JP2022528625A patent/JP2023502108A/ja active Pending
- 2020-11-18 WO PCT/US2020/061130 patent/WO2021102055A1/en unknown
- 2020-11-18 MX MX2022005949A patent/MX2022005949A/es unknown
- 2020-11-18 BR BR112022009611A patent/BR112022009611A2/pt unknown
- 2020-11-18 AU AU2020388577A patent/AU2020388577A1/en active Pending
- 2020-11-18 EP EP20889747.0A patent/EP4061848A4/en active Pending
- 2020-11-18 CN CN202080093841.5A patent/CN116018353A/zh active Pending
- 2020-11-18 US US17/777,591 patent/US20230192846A1/en active Pending
- 2020-11-18 IL IL293026A patent/IL293026A/en unknown
- 2020-11-18 CA CA3161617A patent/CA3161617A1/en active Pending
- 2020-11-18 KR KR1020227019898A patent/KR20220113951A/ko active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
EP4061848A1 (en) | 2022-09-28 |
WO2021102055A1 (en) | 2021-05-27 |
IL293026A (en) | 2022-07-01 |
US20230192846A1 (en) | 2023-06-22 |
MX2022005949A (es) | 2022-08-02 |
EP4061848A4 (en) | 2024-03-20 |
CA3161617A1 (en) | 2021-05-27 |
CN116018353A (zh) | 2023-04-25 |
JP2023502108A (ja) | 2023-01-20 |
AU2020388577A1 (en) | 2022-06-02 |
KR20220113951A (ko) | 2022-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
CL2020001974A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093) | |
CL2023002239A1 (es) | Anticuerpos de b7-h4 y métodos para usarlos | |
CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
PE20191546A1 (es) | Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb | |
ES2523194T3 (es) | Anticuerpo monoclonal humano específico para cada tumor | |
ECSP099656A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
AR106189A1 (es) | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO | |
AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
PE20210652A1 (es) | Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl | |
PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
RS54113B1 (en) | COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN | |
BR112022009611A2 (pt) | Anticorpos anti-ror-2 e métodos de uso | |
RU2018128414A (ru) | Новое psma-связывающее антитело и его применения | |
UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
RU2018137110A (ru) | Антитела против psma и их применение | |
CL2020001726A1 (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
AR073140A1 (es) | Anticuerpos anti-il-23r disenados | |
ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
CL2022003515A1 (es) | Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2 | |
CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
EA201992316A1 (ru) | Композиции и способы для диагностики рака предстательной железы | |
MX2020013606A (es) | Constructos de anticuerpos multiespecificos. | |
PE20230839A1 (es) | Agentes de union a lair-1 y metodos para su uso |